Galapagos NV (GLPG)
| Previous Close | 37.96 |
| Open | 38.18 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 38.09 - 38.42 |
| 52 Week Range | 36.20 - 72.11 |
| Volume | |
| Avg. Volume | 275,444 |
| Market Cap | 2.526B |
| Beta (5Y Monthly) | 0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 61,560 new ordinary shares on 20 March 2023, for a total capital increase (including issuance premium) of EUR 1,769,850.00. In accordance with Belgian transparency legislation1, Galapagos also wishes to note that its total share capital currently amounts to EUR 356,444,938.61, the total number of
- GlobeNewswire
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib, an oral, once daily, JAK1 preferential inhibitor) will be presentedSELECTIONLTE showed that filgotinib maintained a consistent safety profile; symptomatic remission rates and health-related quality of life (HRQoL) improved in patients with moderate to severe active ulcerative colitis (UC)
- GlobeNewswire
Galapagos announces full year 2022 results and outlook for 2023
Key 2022 and post-period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman of the Board of DirectorsImplemented new strategic direction to accelerate innovation and time-to-patients: Set-up of new innovation model and fit-for-purpose R&D organizationFocus on key therapeutic areas of immunology and oncologyDiscontinuation of activities in fibrosis and kidney diseaseExpansion of drug modalities beyond small molecules, including biologicals and CAR-T Entered into the field
